Latest News
Isis Begins Phase III Clinical Trial
On August 1, Isis Pharmaceuticals, Inc. announced today the initiation of a pivotal Phase III study evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA). The Phase III study, ENDEAR, […]
Read More ›Cure SMA Announces New Research Funding
Cure SMA is proud to announce that we will be committing $1.8 million to new research funding over the next 12 months. Fifteen years ago, we had just one potential […]
Read More ›Welcome to Cure SMA
We are excited to announce that Families of SMA is now Cure SMA. In addition to this name change, we’ll also be making a number of other improvements to the […]
Read More ›- « Previous
- 1
- …
- 172
- 173
- 174